Boehringer Ingelheim, a prominent biopharmaceutical company, has secured approval from the Science Based Targets initiative (SBTi) for its ambitious 2030 greenhouse gas (GHG) emission reduction targets. The company is committed to reducing absolute scope 1 and 2 GHG emissions by 58.9 percent and absolute scope 3 GHG emissions by 27.5 percent from 2019 levels.
This validation underscores Boehringer Ingelheim’s dedication to aligning its climate efforts with the 2015 Paris Agreement, signaling a strong commitment to combating climate change.
Boehringer Ingelheim has actively worked on decarbonizing its operations, including making seven of its production sites worldwide carbon-neutral certified. This accomplishment was achieved through the installation of renewable energy solutions and rigorous carbon reduction measures. Additionally, the company has integrated circular economy principles, green mobility concepts, and sustainability building standards at various sites.
Under its MORE GREEN pillar within its Sustainable Development – For Generations program, the company enforces an internal carbon price of EUR 100 per ton of CO2 emissions for investments. It has also allocated EUR 130 million for projects supporting environmental sustainability and has initiated over 60 new environmental sustainability projects since 2020.
Boehringer Ingelheim continues its commitment to mitigating unavoidable emissions by partnering with ClimateSeed, supporting Verified Emissions Reduction projects that safeguard biodiversity and benefit local communities.
The approval from SBTi reflects Boehringer Ingelheim’s unwavering dedication to environmental stewardship and its significant strides in reducing its carbon footprint.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
